KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Financing Cash Flow · Q4 FY2026 · quarter ended Dec 2025
Financing cash flow of $1.47M in Q4 FY2026
Q4 FY2026 financing cash flow was $1.47M. Trailing-twelve-month financing cash flow was $22.93M.
Context
- Financing cash flow amounted to 220.9% of revenue in FY2026.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $1.47M or moves back toward the trailing-twelve-month quarterly average of $5.73M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2026
- 162.64M USD
- Year-over-year change
- +1.8%
- 4-year CAGR
- +218.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | 162.64M | +1.8% |
| FY2025 | 2025-04-30 | 159.73M | +6.0% |
| FY2024 | 2024-04-30 | 150.71M | +159.3% |
| FY2023 | 2023-04-30 | 58.12M | +3575.9% |
| FY2022 | 2022-04-30 | 1.58M | — |
Financing Cash Flow vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 financing cash flow of $22.93M is the 6th largest of the 10 companies compared; the peer median is $6.43M.
- Financing cash flow amounts to 19.8% of revenue for KALV, versus a peer median of 76.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $256.78M | -1.3% | +662.8% | — | |
| LTM Mar 2026 | $224.57M | +85.0% | +72.0% | 452.9% | |
| LTM Mar 2026 | $151.21M | +55.9% | — | 191.0% | |
| LTM Mar 2026 | $124.44M | +575.7% | +232.1% | 141.0% | |
| LTM Mar 2026 | $62.31M | +66.7% | — | 629.9% | |
| LTM Dec 2025 | $22.93M | — | — | 19.8% | |
| LTM Mar 2026 | $10.8M | +25.0% | -54.9% | 3.6% | |
| LTM Mar 2026 | $7.03M | -1150.0% | — | 12.1% | |
| LTM Mar 2026 | $6.43M | +176.3% | -62.0% | 11.6% | |
| LTM Mar 2026 | $143.84K | -100.0% | — | 0.2% | |
| Peer median (excluding KALV) | $6.43M | +55.9% | +72.0% | 76.6% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Depreciation & Amortization | 743K | 718K | 816K | 941K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 9.92M | 21.92M | 12.29M | 0 |
| Change in Working Capital | (12.32M) | 7.41M | 15.17M | 15.04M | 954K |
| Accounts Receivables | (5.2M) | (2.32M) | 8.18M | (3.62M) | (7.4M) |
| Inventory | 0 | 0 | 0 | 0 | (3.43M) |
| Accounts Payables | 1.69M | 1.11M | 4.32M | (4.97M) | 4.19M |
| Other Working Capital | (8.81M) | 8.62M | 2.67M | 23.63M | 7.59M |
| Other Non-Cash Items | 15.78M | (407K) | (485K) | 2.27M | 80.26M |
| Operating Cash Flow | (78.13M) | (75.26M) | (89.23M) | (152.91M) | (81.62M) |
| Capital Expenditures | (931K) | (1.2M) | (443K) | (434K) | (1.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (136.92M) | (98.25M) | (189.23M) | (30.57M) | (84.78M) |
| Sales of Investments | 195.71M | 140.86M | 104.96M | 122.52M | 105.36M |
| Other Investing Activities | 0 | 0 | (401K) | 0 | 0 |
| Investing Cash Flow | 57.86M | 41.42M | (84.72M) | 91.02M | 18.68M |
| Debt Repayment | 0 | 0 | 0 | 98.04M | 160.72M |
| Common Stock Issued | 1.58M | 56.58M | 96.95M | 61.69M | 1.92M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.53M | 53.77M | 0 | 0 |
| Financing Cash Flow | 1.58M | 58.12M | 150.71M | 159.73M | 162.64M |
| Effect of Forex Changes | (1.17M) | 1.24M | (1.21M) | 1.98M | (1.98M) |
| Net Change in Cash | (19.86M) | 25.51M | (24.45M) | 99.83M | 97.73M |
| Free Cash Flow | (79.07M) | (76.46M) | (89.67M) | (153.34M) | (83.33M) |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.